CRISPR

News

Intellia shares fall after hospitalised CRISPR patient dies

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials died.

News

CRISPR biotech Intellia plummets as trial paused for safety

Intellia lost 45% of its value today as phase 3 trials of one of its priority drug programmes were halted due to a patient being hospitalised.

R&D

How a century-old technology could revolutionise LNP charact...

The utility of AUC in LNP characterisation is growing, thanks to ongoing efforts to improve the technology.

R&D

On incentivisation and investment in rare disease R&D

To mark Rare Disease Day, pharmaphorum spoke with Paola Pozzi, partner of telethon strategy at Sofinnova Partners, about the outlook for investment in this field of research.

News

CRISPR biotech Intellia cuts staff as it eyes 2027 launch

Eyeing a first commercial launch in 2027, Intellia is re-prioritising by cutting 27% of its workforce and shelving a lung disease candidate.

News

Intellia trumpets CRISPR drug data, but shares fall

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but i

Intellia shares fall after hospitalised CRISPR patient dies

CRISPR biotech Intellia plummets as trial paused for safety

How a century-old technology could revolutionise LNP charact...

On incentivisation and investment in rare disease R&D

CRISPR biotech Intellia cuts staff as it eyes 2027 launch

Intellia trumpets CRISPR drug data, but shares fall

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

CRISPR

Editor's Picks